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Abstract
Objectives: Primary dysmenorrhoea is a common complaint experienced by many females in 
their reproductive years. The use of medicinal plants in the treatment of various gynaecological 
conditions is on the increase, despite the limited evidence available regarding efficacy and 
safety of their use. The aim of this systematic review was to synthesise the most recent 
evidence relating to the treatment of primary dysmenorrhoea with medicinal plants. 
Methodology: A thorough database search was conducted using defined search terms, and 
randomised controlled trials (RCTs) published in English between 2008 and 2016, pertaining to 
the use of medicinal plants (single use) for the treatment of primary dysmenorrhoea, were 
assessed. Studies evaluating dysmenorrhoeal pain and associated symptoms as a primary or 
secondary outcome were considered and assessed by two reviewers independently of each 
other, using the JADAD scale and the Cochrane risk of bias tool,.
Results: 22 RCTs were included in the review; 9 were placebo-controlled trials and 13 were 
comparative studies to pharmacological treatment or nutritional supplements. Most of the 
evaluated medicinal plants showed evidence of efficacy in relieving menstrual pain in at least 
one RCT. The low or unclear quality of the majority of these studies however warrants caution 
in interpreting these results. 
Conclusion: This review adds to the knowledge-base on the use of these medicinal plants in the 
treatment of primary dysmenorrhoea. Further research is needed before definitive conclusions 
can be made regarding the efficacy and safety of the use of these medicinal plants.
Keywords: medicinal plants, herbal medicines, phytotherapy, primary dysmenorrhoea, 
menstrual pain
1. Introduction
Primary dysmenorrhoea is defined as cyclic pain of uterine origin, without pelvic pathology1; it 
affects up to 81% of menstruating females in their reproductive years2, producing a significant 
negative impact on their quality of life. Pharmacological treatments include the oral 
contraceptive pill (OCP) and/or non-steroidal anti-inflammatory drugs (NSAID’s), however these 
medications have been shown to have numerous side effects3,4. The use of medicinal plants as 
an alternative treatment for dysmenorrhoea is a growing interest amongst many women5,6. 
Previous systematic reviews have been conducted on the effects of medicinal herbs on primary 
dysmenorrhoea. In a systematic review by Mirabi et al. (2014)5, promising evidence was found 
for the use of herbal medicine for primary dysmenorrhoea; this review focused on studies 
conducted on Iranian medicinal plants. Systematic reviews evaluating the use of ginger for 
dysmenorrhoea also found limited evidence of efficacy for this condition7,8. There is a need to 
continually evaluate and summarise research in this area, which is beneficial to both healthcare 
practitioners, as well as their patients.
1.1 Aim
The aim of this systematic review was to determine, evaluate and integrate recent evidence on 
the effectiveness of medicinal plants in the treatment of primary dysmenorrhoea. RCTs related 
to the treatment of females suffering from primary dysmenorrhoea with medicinal plants, in 
comparison to placebo or conventional/nutritional treatment, were considered.
2. Methods
This systematic review was conducted in accordance with PRISMA (Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses) and Cochrane Collaboration guidelines9,10. 
Permission to conduct this study was granted by the Faculty of Health Sciences Higher Degrees 
and Research Ethics Committees at the University of Johannesburg (Clearance numbers: HDC-
01-09-2016/REC-01-11-2016).
2.1 Types of Studies
RCTs involving the treatment of primary dysmenorrhoea using single medicinal plant 
applications compared to placebo or standard pharmaceutical treatment, published between 
2008 and 2016 in English were eligible. Primary or secondary outcomes included evaluating 
menstrual pain and associated symptoms (nausea, vomiting, back pain etc.). Studies scoring 
below 3 on the JADAD scale were excluded.
2.2 Search Strategy
The UJ Health Sciences Databases were initially searched in combination and included: AMED 
(The Allied and Complementary Medicine Database), Health Source: Nursing/Academic Edition, 
Health Source - Consumer Edition, MEDLINE, CINAHL, and SPORTDiscus. The detailed advanced 
search strategy is detailed in Table 1. Language filters for English and date restrictions 
(01/01/2008-30/08/2016) were applied. Thereafter Pubmed, Science Direct, Scopus, Springer 
Link, Wiley Online, Academic Search Complete and Ujoogle databases were also searched. The 
search was last updated on 30/08/2016. The search strategy included free text and Medical 
Subject Heading (MeSH) terms: A (dysmenorrhea, uterine contractility, and menstrual pain) and 
B (herbal medicine, medicinal plants, herbs, herbalism, and phytotherapy). A manual search of 
reference lists of identified studies was also performed. Grey literature was not included in the 
review.
2.3 Evaluation of Studies
Literature was evaluated for relevance by means of the title and abstract. Potentially eligible 
articles were read and assessed by two reviewers independently of eachother. Discrepancies 
were discussed with a third reviewer when necessary. The JADAD scoring system, a widely used 
and validated tool11-13 was used to evaluate the methodological quality of the studies and 
studies with scores of 3 and above were included.  Data from each study was recorded on the 
Joanna Briggs Institute (JBI) data extraction form14, and included: author, year, study design, 
methodology, aim and outcome. Each study was further summarized. The risk of bias was 
assessed as low (+), unclear (?) or high (-) in seven domains, (I = random sequence generation, II 
= allocation concealment, III = blinding of participants / personnel, IV = blinding of outcome 
assessment, V = incomplete outcome data, VI = selective outcome reporting, VII = other bias) 
using the Cochrane Collaboration’s risk of bias tool15, which has become the standard approach 
to assess risk of bias in RCTs16. 
3. Theory
Prevalence rates for primary dysmenorrhoea vary from 45-90% worldwide17, however only a 
small percentage of affected women consult a physician about their condition, and many 
choose to self-medicate18,19. Dysmenorrhoea is typically described as a cramping pain in the 
lower abdomen during menstruation, and other associated symptoms may include urinary 
frequency, diarrhoea, headache, nausea and vomiting20. Dysmenorrhoea is more common in 
young nulliparous females with a family history of dysmenorrhoea; however psychological 
stress and lifestyle factors such as cigarette smoking, and poor diet also increases the risk of 
developing this condition17, 21-24.
The pathophysiology of dysmenorrhoea has been linked to raised levels of prostaglandins 
within the endometrial fluid, which causes increased uterine contractions and peripheral nerve 
hypersensitivity, as well as ischaemia of the myometrium, resulting in menstrual pain25. 
Prostaglandins are synthesized from prostanoids (biologically active derivatives of arachidonic 
acid), through the activity of cyclooxygenase-1 and cyclooxygenase-2 (COX 1 & 2) enzymes, 
which act as catalysts in the production of pro-inflammatory mediators26. NSAIDs (ibuprofen, 
mefenamic acid) are commonly used to alleviate menstrual pain as they inhibit prostaglandin 
production. Adverse effects (such as headaches, drowsiness and gastrointestinal symptoms) 
from NSAID use is common, however is usually dosage dependent27. OCPs suppress ovulation, 
reduce endometrial tissue growth and thereby result in less menstrual bleeding and 
prostaglandin synthesis; adverse effects typically include: headaches, breast tenderness, weight 
gain, and mood swings, as well as an increased risk for developing venous thromboembolism, 
myocardial infarction and stroke25,28. 
Some medicinal plants are reported to bring relief of menstrual symptoms through their 
analgesic, anti-spasmodic, prostaglandin inhibiting or anti-inflammatory actions; these may be 
a suitable alternative to conventional medicines for treating dysmenorrhoea, particularly in 
cases where these medicines are contraindicated or not well tolerated. The mechanism of 
action of many of these plants however is not well understood and needs to be studied 
further5,29,30. Table 2 provides a summary of the effects of the medicinal plants identified in this 
review, relating to primary dysmenorrhoea.
4. Results and findings
A total of 279 unique studies were identified and of these, 252 studies were excluded after 
screening the title and abstract. 27 full text articles were assessed for eligibility and 22 studies 
were included in the review (Figure 1). Appendix A shows the JADAD score, risk of bias 
assessment, and provides a summary of the study characteristics. The inter-rater agreement 
percentage between the two reviewers was 77% (17/22).
The review includes 9 placebo-controlled studies70,79,87,88,90,92,93,97,98, and 13 studies comparing 
efficacy to either NSAIDs (ibuprofen or mefanamic acid)78,80-83,85-87,91,94,96, or nutritional 
supplements84,89.  The following medicinal plants are included: Zingiber officinale (3 RCTs)88-90, 
Foeniculum vulgare (3 RCTs)83-85, Cinnamomum zeylanicum (2 RCTs)78,79, Trigonella foenum-
graecum (2 RCTs)86,87, Mentha piperita (2 RCTs)93,94, Teucrium polium (1 RCT)82, Triticum 
aestivum (1 RCT)97, Rosa damascena (1 RCT)80, Melissa officinalis (1 RCT)91, Morinda citrifolia (1 
RCT)92, Anethum graveolens (1 RCT)81, Achillea millefolium (1 RCT)98, Valeriana officinalis (1 
RCT)70, Rheum emodi (1 RCT)95 and Thymus vulgaris (1 RCT)96. One study each made use of 
tablets92, a liquid extract83, the essential oil96, or essential oil capsules93; two studies made use 
of tea bags91,98, and the rest used dried herbal preparations in the form of capsules. One study84 
compared Foeniculum vulgare with both vitamin E and a placebo; while another85 used a 
combination of Foeniculum vulgare with vitamin E, in comparison to ibuprofen. One open-
labeled 3-arm study86 compared Trigonella foenum-graecum to mefanamic acid and a third 
group that received Trigonella foenum-graecum as well as dry cupping therapy. With regards to 
the sample population, all studies were conducted on university students’ ≥18 years of age with 
moderate to severe dysmenorrhoea; exceptions to this were females aged 12-30 years86, high 
school students aged 15-18 years89, females aged 15-25 years95 and hospital employees, no age 
specified97. Changes in menstrual pain severity was determined using the short form McGill 
pain questionnaire (SF-MPQ)93 and multi-dimensional speech criteria, which was used in one 
study each84, while the visual analogue scale (VAS) was used in all other studies. The Cox 
menstrual symptom scale (COX) was used to evaluate changes in duration of pain in two 
studies78,94. The verbal multidimensional scoring system (VMSS) was used in four 
studies81,90,95,96 to grade the severity of dysmenorrhoea, while the multi-dimensional verbal 
scoring system was used in two studies to assess the severity of associated symptoms (fatigue, 
diarrheoa, nausea, vomiting, lack of energy, syncope, headache, anorexia and mood 
swings)70,87. The pictorial blood assessment chart (PBAC) was made use of in three studies92,94,96 
to quantify the amount of blood loss; while the number of saturated pads were recorded in two 
studies79,83. One study86 aimed to determine safety of Trigonella foenum-graecum treatment 
through clinical examinations and laboratory testing of blood markers. A 5-point Likert scale 
was used to assess response to treatment in one study88, while quality of life was assessed in 
another95.  
Discussion
The limited quantity and quality of the current evidence makes it difficult to draw definitive 
conclusions about the efficacy of medicinal plants in the treatment of primary dysmenorrhoea. 
In this review, four studies83,86,91,95 were found to have a high risk of bias and are therefore not 
considered reliable evidence. Only one study, on the use of Rosa damascena80, had a low risk of 
bias, and therefore can be considered supportive evidence for the potential efficacy of this 
medicinal plant, warranting further investigation. All other studies however, received an 
unclear risk of bias, largely due to insufficient reporting in the published articles. Their results 
should therefore be interpreted with caution. 
Previous research suggests that these medicinal plants have anti-inflammatory and analgesic 
properties, suggesting their possible mechanism of action in the treatment of this condition. 
Based on these studies, as well as the limited safety data in the included trials, it appears that 
these medicinal plants appear to be relatively safe at the dosages used, with either no or only 
minor adverse effects being reported. 
The results of this systematic review can be compared to similar previously conducted studies. 
The systematic review by Mirabi et al. (2014)5, which included 25 RCTs, aimed to determine the 
efficacy and safety of Iranian herbal medicines for primary dysmenorrhoea. The authors found 
evidence of efficacy for the use of Trigonella foenum-graecum, Zingiber officinale, and 
Valeriana officinalis in particular, however recommended further clinical trials necessary to 
evaluate therapeutic dosages and adverse effects. Chen et al. (2016)7 and Daily et al. (2015)8 
conducted systematic reviews on the efficacy of ginger for the treatment of primary 
dysmenorrhoea using 6 and 7 RCTs respectively; both studies concluded that ginger may be 
effective for treating this condition however, future large-scale trials were also recommended 
by the authors to fully evaluate its use and safety. Pattanittum et al. (2016)99 conducted a 
review on dietary supplements for the treatment of primary dysmenorrhoea, and included 27 
RCTs (12 of which related to herbal medicines). The authors concluded that there is no high 
quality evidence to support the effectiveness of any dietary supplement for dysmenorrhoea, 
however more research is justified.
Limitations of the current review is the paucity of eligible RCTs, lack of rigour with regards to 
reporting of results, small sample sizes, and short duration of the trials. Most of these studies 
made use of university students or women in a narrow age range as their population sample, 
and therefore the results cannot be generalized to other age groups. Also, for most medicinal 
plants there was only one included study, and not all studies reported on safety or adverse 
effects. Considering the variety of herbs identified, it is difficult to integrate related evidences 
of efficacy for each one of them. Other limitations of this review include date limitations (2008-
2016) of the inclusion criteria, only selecting trials published in English, and only evaluating 
single herb preparations. Is it recommended that researchers involved in conducting future 
RCTs use checklists such as the one in the CONSORT statement100 to improve the quality of 
their trials and reporting. 
Conclusion
This systematic review provides information regarding the recent clinical evidence on the use of 
medicinal plants for the treatment of primary dysmenorrhoea. Promising evidence was found 
for the efficacy of certain medicinal plants, however the results from these studies needs to be 
interpreted with caution, due to the high or unclear risk of bias, small number of included RCTs 
and poor methodological quality of some of the trials. Only one study was shown to be free of 
bias. This current evidence, together with their long-standing historical use, adds to the 
knowledge-base on the use of these medicinal plants, and further large-scale studies are 
necessary to confirm their beneficial effects, therapeutic dosages, and long-term safety. 
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Search 
number
Search Results
1 Primary dysmenorrhoea (dysmenorrhea) + medicinal plants 765
2 Primary dysmenorrhoea (dysmenorrhea) + herbal medicine (or 
herbs or herbalism)
53
3 Primary dysmenorrhoea (dysmenorrhea) + phytotherapy 528
4 Menstrual pain + medicinal plants 2100
5 Menstrual pain + herbal medicine (or herbs or herbalism) 442
6 Menstrual pain + phytotherapy 1159
7 Uterine contractility + medicinal plants 690
8 Uterine contractility + herbal medicine (or herbs or herbalism) 4247
9 Uterine contractility + phytotherapy 180
Table 1. UJ Health Sciences Database Search Strategy, Updated 30th August 2016
Common name 
Latin name
Family
Effects relating to primary dysmenorrhoea
Main phytochemical constituents 
Proposed mode of action
Recommended dose
Safety
Contraindications / drug interactions
Cinnamon 
Cinnamomum 
zeylanicum
Lauraceae
Antispasmodic, antioxidant, anti-inflammatory31,32 
Cinnamaldehyde, cinnamic acid, eugenol, and various essential oils31,32
Anti-inflammatory activities are believed to be primarily due to its rich 
flavonoid content31,32. Specifically, cinnamon appears to reduce the 
mRNA expression of certain inflammatory mediators, and inhibits the 
expression of COX-2 enzymes33.
3-6g daily of dried herb or 1.5-3.0ml (1:1 g/ml) fluid extract 
daily for < 6 weeks34-36. 
Large quantities should be avoided during pregnancy, in 
patients with gastrointestinal ulcers or allergic 
hypersensitivity34-36. Cinnamon oil is contra-indicated in 
patients with liver conditions or with paracetamol use35. 
Damask rose 
Rosa damascena 
Rosaceae
Analgesic, antispasmodic, anti-inflammatory37,38
Citrenellol, nerol, geranial and kaempferol37,38
The synergistic effects of its active compounds are believed to inhibit 
COX 1 and 2 enzymes, thereby reducing prostaglandin synthesis37,38.
Unknown.  
Damask rose may produce hypersensitivity and 
gastrointestinal effects, which are dose-dependant38.
Dill 
Anethum 
graveolens 
Apiaceae or 
Umbelliferae
Carminative, antispasmodic39,40
Tannins, terpenoids, cardiac glycosides and flavonoids, namely α-
phellandrene, carvone, limonene, dill ether, anethum and sabinene39,40 
Sabinene has been found to inhibit nitric oxide production, and is 
therefore believed to be responsible for dill’s anti-inflammatory 
activity39,40. 
Dill seeds 3g; essential oil 0.1-0.3g daily41.
Side effects are rare; may cause hypersensitivity reactions 
in sensitive persons41.
Felty germander 
Teucrium polium 
Lamiaceae
Anti-inflammatory, antispasmodic, antinociceptive42-44
Neo-clerodane diterpenoids (α-pinene, ocimene, menthane and 
pulegone), flavonoids and aromatic compounds42-44 
Antispasmodic effects are believed to be due to its antagonistic action 
on acetylcholine, histamine and serotonin, and its anti-inflammatory 
effects due to its flavonoid and sterol constituents42-44. 
Unknown. 
Diterpenoids have been implicated in causing 
hepatotoxicity; therefore this medicinal plant should be 
used with caution in patients with hepatic abnormalities42-
44.
Fennel 
Foeniculum vulgare
Apiaceae or 
Carminative, anti-spasmodic, anti-inflammatory, oestrogenic45,46
Fatty acids, phenolic and volatile components; oil contains anethole 
(80%), estragole (10%) and fenchone (7.5%)45-47 
900-1800mg/day (infusion) or 3-6ml/day (1:2 g/ml liquid 
extract)48.
Historical use suggestive of safety45. Potential 
Umbelliferae Reduces the intensity of uterine contractions by inhibiting circulating 
oxytocin and prostaglandins45-47.
carcinogenicity of estragole has led the European Union to 
set limits on daily intake, however other components in 
herb (such as nevadensin, epigallocatechine, and anethole) 
exert a protective effect against estragole47. 
Fenugreek 
Trigonella foenum-
graecum 
Fabaceae
Carminative, analgesic, anti-inflammatory49 
Alkaloids (trigonelline), steroidal saponins (diosgenin and yamogenin), 
flavonoids, oils, coumarins and mucilage50 
Inhibits the synthesis of prostaglandins51. 
5-10g powder taken three times daily or a liquid extract of 
2-6ml/day (1:2 g/ml)36,50. 
Side effects rare; no considerable drug interactions have 
been reported36,50.
Ginger 
Zingiber officinale
Zingiberaceae
Analgesic, anti-inflammatory52,53
Variety of vitamins, minerals, gingerol, shogaols, zingerone, 
sesquiterpenes, capsaicin, and caffeic acid36,53 
Gingerols and shogaols inhibit COX-1 and 2 enzymes, as well as 
lipoxygenase, thereby reducing the synthesis of prostaglandins and 
leukotrienes52,53. 
Up to 4g/day36.
Ginger is overall regarded as safe36. Minor adverse effects: 
gastrointestinal symptoms (eructation, heartburn and 
indigestion)54.
Lemon balm 
Melissa officinalis
Lamiaceae
Antispasmodic, antioxidant, anxiolytic, sedative36,55,56
Triterpenoids, phenolic acids and flavonoids, including α-pinene, citral, 
citronellal, and rosmarinic acid36,55,56 
Rosmarinic acid particularly responsible for antinociceptive and anti-
inflammatory properties; relaxant effects are due to citral36,55,56.
6-12ml/day (1:1g/ml) liquid extract34,36.
Conventional clinical safety data absent; however, long-
standing medicinal use has been documented. Caution in 
patients with thyroid disease, glaucoma, or with sedative 
medications34,36,55,56.
Noni 
Morinda citrifolia
Rubiaceae
Analgesic, anti-inflammatory57,58
Micronutrients, terpenoids, flavonoids, alkaloids, saponins, steroids, 
tannins57,58 
Selectively inhibits COX-1 and 2 enzymes, primarily due to the action of 
scopoletin, quercetin, and ursolic acid36,57-59. 
2g or 25ml juice twice daily36,57,58.
In large doses, may be hepatotoxic and induces 
hyperkalaemia; not recommended in patients with liver or 
kidney dysfunction36,57,58.
Peppermint 
Mentha piperita
Lamiaceae
Antispasmodic, carminative, anti-inflammatory, analgesic60-62.
Menthol, menthone, isomenthone, and low concentrations of 
estragole60-62. 
Inhibits prostaglandin concentration and oxytocin, as well as 
6-9g/day (infusion), or fluid extract 1.5-4.5ml/day (1:2 
g/ml)36,48.
Considered safe for use in the appropriate dosages; should 
be avoided in pregnancy, in patients with gallstones, hiatal 
leukotrienes and interleukins; menthol stimulates ‘cold’ receptors 
(antagonistic effect against calcium channels on neuronal membranes). 
This may explain its antispasmodic and analgesic effects in 
dysmenorrhoea60-62.
hernia and significant gastroesophageal reflux disease 
(GERD). Adverse effects may include allergic reaction and 
gastrointestinal effects34,61.
Rhubarb 
Rheum emodi 
Polygonaceae
Purgative, astringent, analgesic, anti-inflammatory63-65
Anthraquinones (emodin), anthrones, stilbenes (resveratrol), 
oxanthrone and flavonoids63-65
Emodin in particular has been found to have an analgesic action63-65. 
10-30mg/day (0.5-1.5g of dried plant material)66.
Contraindicated in people who have epilepsy, gout, 
rheumatism, or those who have renal or gallbladder 
stones, due to its oxalic content64. 
Thyme 
Thymus vulgaris  
Lamiaceae
Antispasmodic, antioxidant, anticholinergic67
Monoterpenes (namely thymol and carvacrol), flavonoids, synthetic 
resin acids (rosmarinic acid, caffeic acid)67
Believed to be helpful in treating dysmenorrhoea due to its 
anticholinergic effects and ability to block serotoninergic pathways67. 
3-12g/day (infusion), liquid extract of 2-6ml/day (1:2 g/ml), 
tincture 6-18ml/day (1:5 g/ml)36,48.
Reported adverse events are mild; contraindicated in 
patients with gastritis, enterocolitis, congestive heart 
failure, as well as hypersensitive individuals34,36,68. 
Valerian 
Valeriana officinalis
Valerianaceae
Sedative, anxiolytic, antispasmodic69
 Sesquiterpenoids (valerenic acid), epoxy iridoid esters (valepotriates, 
valtrate), amino acids (γ-aminobutyric acid, tyrosine), alkaloids69 
Valepotriates (and valtrate) are responsible for valerian’s spasmolytic 
activity, by influencing the binding of calcium ions to smooth muscle 
(musculotrophic action)70,71. 
3-9g/day (infusion) or 2-6ml/day (fluid extract 1:2 
g/ml)36,48.
Adverse effects are rare and it has a favourable safety 
profile72. 
Wheat germ 
Triticum aestivum
Poaceae
Fibre, α-tocopherols (vitamin E), sterols, phytosterols and flavonoids73-75 
Vitamin E is a potent antioxidant and anti-inflammatory, and 
supplementation has been shown to alleviate the severity of pain in 
females with primary dysmenorrhoea73-75. 
Unknown.
Caution: people who are gluten intolerant or have coeliac 
disease. Mild adverse effects such as diarrhoea, flatulence, 
nausea and vertigo have been recorded73,75.
Yarrow 
Achillea millefolium
Asteraceae
Antispasmodic, anti-inflammatory76
Flavonoids, alkaloids (achilleine), cineol, borneol, α & β pinene, 
camphor, caryophyllene, thujene, rutin, monoterpenoids and 
sesquiterpenoids.76 
The antispasmodic effects are believed to be due to: anti-prostaglandin 
2-4g/day (dried herb) or 15-40ml/day (fluid extract 1:2 
g/ml)36,48.
The medicinal use of yarrow can be considered safe; 
however hypersensitivity reactions are possible77. 
Table 2. Identified Medicinal Plants Used in the Treatment of Primary Dysmenorrhoea 
effects, blockade of voltage dependent calcium channels, blockade of 
beta-adrenergic receptors and inhibition of NO synthesis76. 
Appendix A: Characteristics of included studies
Cinnamon (Cinnamomum zeylanicum) Jaafarpour et al. (2015a) 78                                                                                                                JADAD Score: 
5
Methods RCT, 3 parallel arms
Participants n = 114; Mean age placebo (21.3), ibuprofen (20.8), cinnamon (20.7)  
Inclusion: female students aged 18-30; regular menstrual cycles; moderate primary dysmenorrhoea; lack of chronic diseases; 
absence of vaginal symptoms (burning, itching, discharge), pelvic inflammatory disease, tumour, fibroma; lack of recent 
stressors; Body mass index (BMI) 19-26. Exclusion: Use of OCP, medicines, plant allergy and mild dysmenorrhoea. 
Setting: Ilam University of Medical Sciences, Western Iran.
Interventions Cinnamon (1260mg) (n = 38)/ ibuprofen (1200mg) (n = 38)/ placebo (starch) (n = 38), daily on days 1-3 for one menstrual cycle
Outcomes VAS (severity of pain) assessed at different time intervals during first 72 h of cycle, and Cox Menstrual Scale (duration of pain) 
assessed once daily.
Notes The mean pain severity and duration was significantly reduced in the treatment groups (p < 0.001); this was in favour of the 
cinnamon group in the first 8 hours. The researchers did not report on adverse effects therefore no conclusions can be made 
with regards to its safety profile.
Limitations  Small sample size and short duration (one cycle)
Risk of Bias: Unclear (domains I, VI)
Jaafarpour et al. (2015b) 79                                                                                                                                                                                       JADAD Score: 
4
Methods RCT, 2 parallel arms
Participants n = 76; Mean age placebo (21.3), cinnamon (20.7)  
Inclusion: female students aged 18-30; regular menstrual cycles; moderate primary dysmenorrhoea; digestive disorder 
(nausea or vomiting) with dysmenorrhoea, lack of chronic diseases; absence of vaginal symptoms (burning, itching, discharge), 
pelvic inflammatory disease, tumour, fibroma; lack of recent stressors; BMI 19-26. Exclusion: Use of OCP, receiving analgesics 
during study period, medical or herbal allergy. 
Setting: Ilam University of Medical Sciences, Western Iran.
Interventions Cinnamon (420mg) (n = 38)/ placebo (starch) (n = 38), taken three times a day, on days 1-3 for one menstrual cycle
Outcomes VAS (severity of pain and nausea), vomiting (frequency counted), menstrual bleeding (number of saturated pads counted) 
assessed at different time intervals during first 72 h of cycle.
Notes The mean severity of pain, nausea, vomiting and menstrual bleeding in the cinnamon group was significantly less than placebo, 
at various intervals (p < 0.05).
Limitations  Small sample size and short duration (one cycle)
Risk of Bias: Unclear (domains I, II, VI)
Damask rose (Rosa damascena) Bani et al. (2014) 80                                                                                                                                         JADAD Score: 
5
Methods RCT, crossover design, 2 parallel arms
Participants n = 92; Mean age damask rose (22.2), mefanamic acid (22.13)  
Inclusion: single female students aged 18-24; BMI 19-25; pain score 5-8 on VAS, no history of abdominopelvic surgery, not 
prohibited from taking herbs or NSAID’s (renal, hepatic, gastrointestinal disease). Exclusion: Occurrence of stressful event, use 
of drugs that interact with NSAIDs, use of OCPs and lack of compliance.
Setting: Kowsar Dormitory of Tabriz University of Medical Sciences, Iran.
Interventions Damask rose extract (200mg) (n = 46)/ mefenamic acid (250mg) (n = 46), every 6 hours on days 1-3.
Outcomes VAS (severity of pain) assessed at different time intervals during first 72 h of cycle.
Notes VAS scores validated a significant difference between the average pain intensity in each intervention group after each cycle (p 
< 0.001), and there was no significant difference between the groups (cycle 1 p = 0.35; cycle 2 p = 0.22). Damask rose therefore 
had similar effects to mefenamic acid for reducing the severity of menstrual pain. No adverse effects were reported in this 
study.
Risk of Bias: Low
Dill (Anethum graveolens) Heidarifar et al. (2014) 81                                                                                                                                         JADAD Score: 5
Methods RCT, 3 parallel arms
Participants n = 75; Mean age placebo (20.95), dill (20.95), mefanamic acid (22.04)  
Inclusion: single female students aged 18-28; primary dysmenorrhoea. Exclusion: history of pelvic or organic disorders; 
gastrointestinal, urogenital, heamatological or other systems disorders; irregular menstrual cycles; taking any drug; previous 
sensitivity to NSAIDs or dill; mild dysmenorrhoea. 
Setting: Nursing and Midwifery School and Paramedical Faculty of Qom University of Medical Sciences, Iran.
Interventions Dill (2g) (n = 23 analysed) / mefenamic acid (500mg) (n = 24 analysed) / placebo (1g) (n = 23)
Outcomes VAS and verbal multidimensional scoring (VMS) completed after each cycle, for 2 months.
Notes The dill group had a statistically significant decrease in pain severity over the two cycles (p < 0.0001), comparable to the 
mefenamic acid group (p > 0.05), and a similar decrease in VMS grading. A few participants in each group reported minor 
adverse effects, but the difference between the groups for adverse effects was insignificant (p = 0.621).
Limitations  Small sample size
Risk of Bias: Unclear (domains I, VI)
Felty germander (Teucrium polium) Abadian et al. (2016) 82                                                                                                                           JADAD Score: 4
Methods RCT, 2 parallel arms
Participants n = 70; Mean age Felty germander (21), mefanamic acid (21)  
Inclusion: single female dormitory students with moderate to severe dysmenorrhoea. Exclusion: underlying disease (Diabetes, 
hypertension, infectious disease); irregular menstruation, endometriosis, history of medication usage, experiencing acute 
stress; vaginal symptoms (burning, itching, irritation, discharge); allergy to herbs. 
Setting: Shahid Beheshti University, Tehran, Iran.
Interventions Felty germander (1g) (n = 35) / mefenamic acid (1g) (n = 35), daily on days 1-3
Outcomes VAS completed 3 times daily for first three days of menses, for 2 consecutive months.
Notes Both groups showed a significant reduction in pain severity over time (p = 0.001), and there was no difference between the 
groups (p = 0.52). No adverse effects were recorded by participants for the duration of the study.
Limitations  Small sample size
Risk of Bias: Unclear (domains V, VI)
Fennel (Foeniculum vulgare) Bokaie et al. (2013) 83                                                                                                                                           JADAD Score: 
3
Methods RCT, 2 parallel arms
Participants n = 60; Mean age fennel (21.07), mefanamic acid (21.17)  
Inclusion: single female dormitory students 18-25 years with moderate to severe primary dysmenorrhoea; non-smoker; no 
systemic disease; not using OCP or hormonal or herbal drugs prior to and during menstrual cycle; regular menstrual cycle. 
Exclusion: intolerance to fennel drops, not willing to take treatments, taking NSAIDs during study. 
Setting: Roghaye dormitory, Shahid Sadoughi University of Medical Sciences, Iran.
Interventions Fennel 2% (25 drops containing 15.5mg/ml antole) (n = 29 analysed)/ mefenamic acid (250mg) (n = 30), every 6 hours. 
Participants could use mefanamic acid if necessary
Outcomes VAS (pain severity), bleeding (pad consumption), NSAID usage recorded for first three days of menses, for 2 consecutive 
months.
Notes No significant differences between the groups in terms of pain intensity or severity of bleeding (p > 0.05). The study group 
used significantly less NSAIDs than the control group (p < 0.05). Results suggest that the efficacy of fennel drops is comparable 
to mefenamic acid. Protocol compliance was difficult due to the offensive smell and taste of the fennel drops.
Limitations  Small sample size. Fennel drops unpleasant, affected compliance. 
Risk of Bias: High (domain II): due to the inability to ensure blinding of participants (drops versus capsules).
Moslemi et al. (2012) 84                                                                                                                                                                                             JADAD Score: 
5
Methods RCT, 3 parallel arms
Participants n = 79; Mean age fennel (25.05), vitamin E (23.25), placebo (25.9)  
Inclusion: single female medical students 18-25 years with mild or acute dysmenorrhoea; regular menstrual cycle; lack of any 
known diseases; allergies to drugs or herbal remedies; no stressful occurrence in previous 6 months. 
Setting: Sari Branch of Azad University of Medical Sciences, Iran.
Interventions Fennel (46mg) (n = 22 analysed)/ vitamin E (100mg) (n = 20 analysed)/ placebo (n = 21 analysed), every 6 hours, on days 1-3. 
Participants could use analgesics if necessary.
Outcomes Multi-dimensional speech criteria scale (pain severity), for 2 consecutive months.
Notes There was no significant difference between the groups for pain severity in the first cycle, but pain scores were significantly 
lower in the fennel group in the second cycle (p < 0.05).
Limitations  Small sample size and high attrition rate
Risk of Bias: Unclear (domains II, V)
Nasehi et al. (2013) 85                                                                                                                                                                                                JADAD Score: 
4
Methods RCT, crossover design
Participants n = 68; Mean age whole sample (21.8) 
Inclusion: female students with history of primary dysmenorrhoea; regular menstrual cycle; no previous history of 
gynaecologic disease or pelvic surgery or seizure; allergy to NSAIDS or contraindication to herbal remedies; no stressors in last 
6 months; no gastrointestinal disorder or other disease that may affect study results. Exclusion: pain for duration of menstrual 
period or before onset; use of OCP; urinary infection during study period; participation in another clinical study prior or during. 
Setting: Tabriz University and Tabriz University of Medical Sciences, Iran.
Interventions 60 mg fennel extract/150 IU vitamin E combination (n = 34)/ ibuprofen (400mg) (n = 34) 4 times daily for first 2 days of cycle
Outcomes VAS (pain severity), recorded at various time intervals for first 48h, for 2 consecutive months.
Notes Results revealed that the mean maximum pain intensity in the fennel and vitamin E group was lower than in the ibuprofen 
group, but was only statistically significant in the first (p < 0.03) and second (p < 0.04) hours.
Limitations  Small sample size and high attrition rate
Risk of Bias: Unclear (domain V)
Fenugreek (Trigonella foenum-graecum) Inandmar et al. (2012) 86                                                                                                               JADAD Score: 3
Methods RCT, open-labelled
Participants n = 60; Mean age fenugreek (17.7), fenugreek + dry cupping (19.1), mefanamic acid (18.05)  
Inclusion: females aged 12-30 years with primary dysmenorrhoea; regular menstrual cycle. Exclusion: congenital abnormalities 
of uterus; secondary dysmenorrhoea; organic pelvic pathology; membranous dysmenorrhoea; systemic illness; use of OCP or 
other hormones. 
Setting: India.
Interventions Group 1:Fenugreek (6g/day) (n = 20); Group 2: fenugreek (6g) daily on days 1-3 & 15 minutes dry cupping therapy on days 1 
& 3 (n = 20); Group 3: mefenamic acid (1000mg/day) (n = 20).
Outcomes VAS (pain severity), for 3 consecutive cycles. Safety assessed by means of laboratory tests (coagulation profile, full blood count, 
and liver and kidney function markers).
Notes All three groups had a significant reduction in lower abdominal pain (p < 0.001) and the percentage of pain reduction was 
66.89%, 66.49%, and 62.88% in groups 1, 2 and 3 respectively. No significant reduction in backache (p > 0.05) occurred. All 
blood markers stayed within normal range, hence fenugreek may be safe to use in these dosages.
Limitations  Small sample size
Risk of Bias: High (domains II, III): due to the nature of this study, there was a high risk of bias due to lack of participant and assessor blinding.
Younesy et al. (2014) 87                                                                                                                                                                                            JADAD Score: 5
Methods RCT, 2 parallel arms
Participants n = 101; Mean age fenugreek (19.86), placebo (20)  
Inclusion: single female dormitory students with moderate to severe dysmenorrhoea. Exclusion: underlying disease (diabetes, 
hypertension, infectious diseases); irregular menstrual cycles; endometriosis; history of medication use; acute stress; vaginal 
symptoms (burning, itching, irritation, discharge); allergy to fenugreek/plants; use of herbal drugs in previous 3 months. 
Setting: Shahid Beheshti University, Tehran, Iran.
Interventions Fenugreek (900mg) (n = 51 analysed)/ placebo (starch) (n = 50 analysed), 2-3 capsules three times a day on days 1-3. 
Participants could use analgesics if necessary.
Outcomes VAS (pain severity), measured 3 times daily on first 3 days of cycle; multidimensional verbal scoring system (associated 
systemic symptoms); use of analgesics (checklist); for 2 consecutive cycles. 
Notes Fenugreek produced a statistically significant reduction in pain intensity (p < 0.001), compared to placebo, as well as a 
significant reduction in duration of pain (p < 0.001), sedative use (p < 0.01), and systemic symptoms (p < 0.001); no inter-group 
analysis was provided.
Limitations  Small sample size. No evaluation of adverse effects.
Risk of Bias: Unclear (domains II, V)
Ginger (Zingiber officinale) Jenabi (2013) 88                                                                                                                                                         JADAD Score: 
3
Methods RCT, 2 parallel arms
Participants n = 70; Mean age placebo (21.54), ginger (21.33)
Inclusion: single female students with primary dysmenorrhoea, scoring >3 on VAS for pain. Exclusion: mild dysmenorrhoea. 
Setting: Toyserkan Azad University, western Iran.
Interventions Ginger (1500mg) (n = 35)/ placebo (n = 34 analysed), daily on days 1-3.
Outcomes VAS (severity of pain) and 5-point Likert scale (response to treatment), for 1 menstrual cycle.
Notes Results revealed a statistically significant improvement in severity of pain in the ginger group (p=0.001), with 82.85% of 
subjects reporting an improvement in their symptoms. No adverse effects were reported in the ginger group.
Limitations  Small sample size and short duration of study
Risk of Bias: Unclear (domains III, IV)
Kashefi et al. (2014) 89                                                                                                                                                                                                JADAD Score: 
5
Methods RCT, 3 parallel arms
Participants n = 150; Mean age whole sample (17)
Inclusion: female high school students 15-18 years with primary dysmenorrhoea; regular menstrual cycles; pain on first 3 days 
of menses; scoring >4 on VAS for pain. Exclusion: secondary dysmenorrhoea due to underlying disease/disorder; use of 
hormonal medications (OCP); use of analgesics. 
Setting: Bojnurd, Iran.
Interventions Ginger (750mg) (n = 56)/ zinc sulphate (660mg) (n = 48)/ placebo (lactose) (n = 46), daily, 1 day before menses until day 3.
Outcomes PVAS (severity of pain) every 24h for first 3 days of cycle, for 2 menstrual cycles.
Notes Both the ginger and zinc groups experienced a statistically significant reduction in severity of pain as compared to the placebo 
(p < 0.05). Minimal adverse effects were reported in all three groups, namely: diarrhoea, heartburn and headaches, with no 
significant difference found between the groups.
Risk of Bias: Unclear (domains II, V)
Rahnama et al. (2012) 90                                                                                                                                                                                            JADAD Score: 
5
Methods RCT, 2 parallel arms
Participants n = 118; Mean age placebo (21.3), ginger (21.4)
Inclusion: single female students > 18 years with moderate to severe primary dysmenorrhoea, scoring 2 or 3 on VMSS; regular 
menstrual cycle. Exclusion: diagnoses of a disease; history of pregnancy or use of OCP; BMI <19 or > 25; mild dysmenorrhoea. 
Setting: Shahed University, Tehran, Iran.
Interventions Ginger (1500mg) (n = 59 analysed)/ placebo (n = 46 analysed), daily. Protocol 1: capsules taken 2 days before menses until day 
3. Protocol 2: capsules taken days 1-3.
Outcomes VAS (severity of pain) and duration of pain (number of hours); first 3 days of menses for 2 menstrual cycles (protocol 1 & 2).
Notes Significant differences in the severity of pain between groups for protocols 1 (p = 0.015) and 2 (p = 0.029); a significant 
difference in the duration of pain was seen in protocol 1 (p = 0.016) only. Duration of pain was 11 hours less in the ginger 
group than the placebo. Ginger appeared to be very well tolerated, with 5.1% of participants’ experiencing heartburn, while 
8.7% in the placebo group reported nausea.
Limitations  High attrition rate in placebo group
Risk of Bias: Unclear (domains V, VI)
Lemon balm (Melissa officinalis) Dehcheshmeh & Parvin (2016) 91                                                                                                                JADAD Score: 
3
Methods RCT, 2 parallel arms
Participants n = 60; Mean age lemon balm (24.55), mefanamic acid (25.38)  
Inclusion: single females aged >17 years with moderate to severe dysmenorrhoea; scored > 3 on VAS for pain; regular 
menstrual cycles. Exclusion: secondary dysmenorrhoea; history of pelvic inflammatory diseases; vaginal infection; OCP or 
intrauterine device use; any known disorders (gastrointestinal, urogenital, haematological, systemic, psychological); use of 
analgesics; hypersensitivity to NSAIDs or lemon balm.  
Setting: Hajar Hospital, Shahrekord University of Medical Sciences, Iran.
Interventions Lemon balm (tea bags) (n = 22 analysed)/ mefenamic acid (250mg) (n = 21 analysed), every 8 hourly on days 1-3.
Outcomes VAS (pain severity), pain duration recorded, on first 3 days of menstruation for 3 consecutive cycles. 
Notes Both mefanamic acid and lemon balm use resulted in a significant reduction in menstrual pain (p < 0.001) and had a similar 
effect on duration of pain (p = 0.101).
Limitations  Small sample size and high attrition rate
Risk of Bias: High (domains II, III): due to the nature of the intervention (teabags versus capsules), blinding could not be achieved.
Noni (Morinda citrifolia) Fletcher et al. (2013) 92                                                                                                                                                JADAD Score: 
5
Methods RCT, 2 parallel arms
Participants n = 100; Mean age placebo (22), noni (22.7)  
Inclusion: female students aged >18 years with dysmenorrhoea. Exclusion: history of previous surgery, pelvic surgery, 
hypersensitivity to Noni, liver disease or suspected pregnancy. 
Setting: Colleges in Kingston metropolitan area, Jamaica.
Interventions Noni (800mg) (n = 42 analysed)/ placebo (glucose) (800mg) (n = 38 analysed), daily 2 days prior to menses until day 3. 
Participants could use analgesics if necessary.
Outcomes VAS (severity of pain), PBLC (blood loss) assessed for 3 menstrual cycles. Haemoglobin (Hb), haematocrit and erythrocyte 
sedimentation rate conducted at beginning and end of trial.
Notes No significant difference between groups with regards to blood loss scores (p = 0.405), Hb (p = 0.6) and pain (no p-value 
provided); the treatment group had a lower ESR level at the end of the study (p = <0.02). Noni did not produce a reduction in 
pain intensity or blood loss but may have an anti-inflammatory effect.
Limitations  Small sample size. High refusal rate at recruitment (71.4%).
Risk of Bias: Unclear (domains VI)
Peppermint (Mentha piperita) Heshmati et al. (2016) 93                                                                                                                                  JADAD Score: 5
Methods RCT, 2 parallel arms
Participants n = 102; Mean age placebo (20.09), peppermint (21.02)  
Inclusion: single female dormitory students aged 18-26 years with menstrual pain in first 3 days for 3 consecutive periods over 
the previous 6 months; moderate to severe primary dysmenorrhoea; regular menstrual cycles; BMI 19.8-26; no vaginal 
symptoms of burning, itching or discharge. Exclusion: professional athletes; chronic disorders (diabetes, hypertension, 
cardiovascular, hepatic or renal disorders, infectious disease, epilepsy); use of herbal medicines or supplements in previous 3 
months or any other special medications; pelvic pathology.
Setting: North Khorosan University of Shirvan, Iran
Interventions Peppermint extract (990mg) (n = 46 analysed) / placebo (1500mg), (n = 44 analysed), daily on days 1-3. Participants could use 
analgesics if necessary.
Outcomes SF-MPQ (severity of pain), assessed first 3 days of cycle for 2 menstrual cycles. 
Notes SF-MPQ showed a statistically significant difference in terms of pain severity in favour of the treatment group in the 1st (p = 
0.014) and 2nd cycles (p = 0.008), however not for duration of pain (p > 0.05). No adverse effects were reported.
Risk of Bias: Unclear (domains II, VI)
Masoumi et al. (2016) 94                                                                                                                                                                                            JADAD Score: 
5
Methods RCT, crossover study
Participants n = 127; Mean age whole sample (20.99)  
Inclusion: single female students aged 18-25 years with primary dysmenorrhoea; regular menstrual cycles. Exclusion: allergy 
to mint or mefanamic acid, patients with cholecystitis, gastroesophageal reflux or liver diseases, kidney disease, ulcers, blood 
dyscrasia, asthma, diabetes or extreme sensitivity to aspirin.   
Setting: Hamadan, Iran
Interventions Peppermint oil (0.2ml capsule), taken daily on days 1-3 (n = 61 analysed / mefenamic acid (250mg) (n = 61 analysed), every 8 
hourly on days 1-3. Use of analgesics were permitted if necessary.
Outcomes VAS (severity of pain), COX menstrual symptom scale (duration), PBAC (blood loss), analgesic use, and nausea and diarrhoea 
asked about; assessed for 3 menstrual cycles. 
Notes Significant improvement in the duration and severity of pain (p = 0.001) and need for analgesics was similar in both groups (p 
= 0.289); no significant difference between groups for severity (p = 0.098) while the control experienced a shorter duration of 
bleeding (p = 0.017). The peppermint group had a greater reduction in nausea (p = 0.001) and diarrhoea (p = 0.002).
Limitations  Reasons for withdrawal not reported
Risk of Bias: Unclear (domains V)
Rhubarb (Rheum emodi) Rehman et al. (2015) 95                                                                                                                                               JADAD Score: 5
Methods RCT, 2 parallel arms
Participants n = 45; Mean age placebo (17.73), rhubarb (18.87)  
Inclusion: single females aged 15-25 years with moderate to severe dysmenorrhoea; regular menstrual cycles. Exclusion: pelvic 
pathology, irregular cycles, systemic illness, married women, allergic to NSAIDs, or mild dysmenorrhoea.   
Setting: Bangalore, India.
Interventions Rhubarb (840mg) (n = 30), / mefenamic acid (750mg) (n = 15), daily, 2 days before menses until day 3.
Outcomes VAS (severity of pain), VMSS (duration), associated symptoms on 0-3 grading scale, and QOL; assessed for 3 menstrual cycles. 
Safety assessed by biochemic markers at beginning and end of study.
Notes Pain severity and duration was significantly improved in both groups (p < 0.001), with no significant difference between the 
groups (p = 0.236; p = 0.089 respectively). Associated symptoms and QOL were also significantly improved in both groups (p 
< 0.001), with no significant difference found between the groups. Minor adverse effects were reported by 6 participants in 
this study. Only the baseline blood test results were reported in the article therefore it is unknown what effect rhubarb had 
on biochemic markers.
Limitations  Small sample size
Risk of Bias: High (domain I): investigator assigned participants to the group and therefore knew what each participant would receive.
Thyme (Thymus vulgaris) Salmalian et al. (2014) 96                                                                                                                                            JADAD Score: 
3
Methods RCT, 3 parallel arms
Participants n = 84; Mean age whole sample (20.52)
Inclusion: single female students aged 18-24 years with primary dysmenorrhoea rated at grade 1 or 2 in their current cycle, 
and at least in their past two cycles, that did not use analgesics 48h before onset of study. Exclusion: history of abdominal or 
pelvic surgery, diagnosed liver or kidney disease, severe stress up to 6 months before study, doing heavy exercise, history of 
allergy to thyme or ibuprofen, or poor compliance.   
Setting: Babol University of Medical Sciences, Iran.
Interventions Group 1 (n = 28): 25 drops placebo essential oil + ibuprofen (200mg); group 2 (n = 28): 25 drops of thyme essential oil + placebo 
capsule; group 3 (n = 28): 25 drops of placebo essential oil + placebo capsule, every 6 hours with the onset of pain.
Outcomes VAS (severity), VMSS (severity of dysmenorrhoea), PBAC (blood loss); for 2 menstrual cycles. Satisfaction with treatment self-
rated at the end of the study.
Notes Significantly reduced severity of pain (p < 0.001), and associated symptoms (nausea and vomiting) in both the thyme (p < 0.04) 
and ibuprofen (p < 0.01) groups respectively; there was no difference between the two groups. No significant change in 
menstrual bleeding was reported. The majority of participants in the thyme group rated satisfaction with treatment as ‘great’, 
the ibuprofen group as ‘moderate’ and the placebo group as ‘ineffective’.
Limitations  Small sample size
Risk of Bias: Unclear (domains II, V)
Valerian (Valeriana officinalis) Mirabi et al. (2011) 70                                                                                                                                        JADAD Score: 
5
Methods RCT, 2 parallel arms
Participants n = 100; Mean age placebo (21.04), valerian (20.90)
Inclusion: single female dormitory students with moderate to severe dysmenorrhoea. Exclusion: chronic medical conditions, 
use of medications, experienced acute stress, irregular menstrual cycles, or had vaginal symptoms (burning, itching or 
discharge).   
Setting: Islamic Azad University, Zanjan, Iran.
Interventions Valerian (675mg) (n = 51 analysed)/ placebo (n = 49 analysed), daily on days 1-3. Use of analgesics were permitted if necessary.
Outcomes VAS (severity) and multidimensional verbal scoring system (associated symptoms); assessed for 2 menstrual cycles
Notes Severity of pain decreased significantly in favour of the valerian group (p < 0.001). Associated symptoms reduced similarly 
over time (p < 0.001), however, the differences between the two groups were not significant, except for syncope. The valerian 
group required fewer sedative tablets (NSAIDs) than the placebo group (p < 0.001). No participants reported adverse effects 
from the use of valerian, however one participant did withdraw from the valerian group due to dizziness, which may be a side 
effect. 
Risk of Bias: Unclear (domains II, VI)
Wheat germ (Triticum aestivum) Ataollahi et al. (2014) 97                                                                                                                               JADAD Score: 3
Methods RCT, 2 parallel arms
Participants n = 90; Mean age placebo (32.84), wheat germ (33.45)
Inclusion: female employees of hospitals affiliated to Hamadan University of Medical Sciences with primary dysmenorrhoea. 
Exclusion: known physical or mental disease, surgery or adverse events in previous 3 months, known chronic pelvic disease, 
use of contraceptives in previous 3 months, pregnancy or pain for the whole menstrual period.
Setting: Hamadan University of Medical Sciences, Iran.
Interventions Wheat germ extract (1200mg) (n = 45)/ placebo (1200mg) (n = 45), daily, between the 16th and 5th day of the consecutive 
menstrual cycle
Outcomes VAS (severity of dysmenorrhoea) assessed for 2 menstrual cycles.
Notes Results showed a significant reduction in pain severity over time (p < 0.001) in the treatment group, and between groups (p = 
0.003). Ten participants withdrew from the study, however it is unclear how many participants from each group were analysed. 
A few participants in both groups reported side effects but these were not specified or significantly different between the 
groups (p = 0.556).
Limitations  Small sample size
Risk of Bias: Unclear (domains I, II, III, V)
Yarrow (Achillea millefolium) Jenabi & Fereidoony (2015) 98                                                                                                                           JADAD Score: 
5
Methods RCT, 2 parallel arms
Participants n = 96; Mean age placebo (20.37), yarrow (21.66)
Inclusion: single female students aged 19-23 years with moderate to severe primary dysmenorrhoea (> 3 on VAS), regular 
menstrual cycles for past 3 months, no hormonal treatment, no use of other medication for menstrual pain, no clinical history 
of major psychological problems. Exclusion: secondary dysmenorrhoea.   
Setting: Islamic Azad University, Iran.
Interventions Yarrow (4g tea bag in 300ml hot water p/teacup) (n = 45 analysed)/ placebo (starch) (n = 46 analysed), 3 times a day on days 
1-3.
Outcomes VAS (severity) assessed for 2 menstrual cycles.
Notes The severity of pain from baseline to post-therapy in the yarrow group was significantly greater than that of the placebo, for 
the first (p = 0.001) and second months (p < 0.0001).
Limitations  Small sample size
Risk of Bias: Unclear (domains VI)
